Clinical trials: Pulmonary Tuberculosis (TB)
Tuberculosis, Multidrug-Resistant
Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)
This study is to evaluate the effectiveness and safety of a 9-month MDR-END regimen as a treatment for fluoroquinolone-sensitive multidrug resistant pulmonary tuberculosis in the real-world clinical setting.
- Trial name
- NCT06674291
- Testing
- No intervention (observational study)
- Volunteers
- 222 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Tuberculosis, Tuberculosis, Pulmonary
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
This is a randomized, double-blind, placebo-controlled, single ascending dose study conducted at one study center in the United States. Four (4) cohorts of 8 subjects each (6 active and 2 placebo).
- Trial name
- NCT03199313
- Testing
- Sutezolid
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Tuberculosis (TB)
A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease
The goal of this clinical trial is to evaluate if N-acetylcysteine (NAC) works to prevent post-tuberculosis lung disease (PTLD) in patients with severe pulmonary impairment. It also aims to assess the safety of NAC.
- Trial name
- NAC-PTLD (NCT06909799)
- Testing
- N-Acetyl Cysteine (NAC), Standard TB treatment
- Where
- The Gambia
- Volunteers
- 242 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis, Pulmonary Tuberculosis
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
The METHOD study will examine whether adding metformin to standard antibiotic treatment for tuberculosis (TB) in people with HIV is safe and well tolerated.
- Conditions
- Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection
- Trial name
- METHOD (NCT04930744)
- Testing
- Isoniazid, Rifampicin, Ethambutol
- Where
- 2 sites in South Africa
- Volunteers
- 112 people
- Sponsor
- University of Massachusetts, Worcester
Tuberculosis, Pulmonary
Conventional Bronchoscope With BAL vs. Thin Bronchoscope With BW to Diagnose Pulmonary TB
This study aims to compare the diagnostic yield of bronchoalveolar lavage (BAL) using a thick conventional bronchoscope and bronchial washing (BW) using a thin bronchoscope in the diagnosis of pulmonary tuberculosis.
- Trial name
- NCT06159023
- Testing
- bronchial washing using a thin bronchoscope
- Where
- South Korea
- Volunteers
- 132 people
- Sponsor
- Pusan National University Hospital
Tuberculosis, Pulmonary
VDOT and Mobile Payments in Cambodia
This project proposes to develop and pilot a novel smart phone-based intervention to improve tuberculosis (TB) treatment adherence in Cambodia, which integrates video-enabled Directly Observed Treatment (vDOT) with an automated…
- Trial name
- NCT03547479
- Testing
- VDOT, VDOT + mobile money
- Sponsor
- University of Southern California
Tuberculosis
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB
- Trial name
- NCT00910871
- Testing
- TMC207, Background Regimen (BR) for MDR-TB
- Where
- 27 sites in China, Estonia and 10 more
- Volunteers
- 241 people
- Sponsor
- Janssen Infectious Diseases BVBA
Pulmonary TB
Comparison Between Two Strategies for the Diagnosis of TB
Tuberculosis (TB) is a major cause of death among the "communicable" diseases in the world. Pulmonary TB, the main localization, leads to the dissemination of cases.
- Trial name
- NCT02961569
- Testing
- sputum collection for acid fast bacilli
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Hopital Lariboisière
Tuberculosis, Pulmonary, Household Contacts
Airborne Preventive Measures to Reduce New TB Infections in Household Contacts
Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS).
- Conditions
- Tuberculosis, Pulmonary, Household Contacts, Tuberculosis
- Trial name
- TBMask (NCT04938596)
- Testing
- Respiratory bundle
- Where
- Chile
- Volunteers
- 432 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Tuberculosis, Pulmonary
Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis
New approaches are needed to achieve more rapid elimination of dormant mycobacteria and thereby shorten treatment for drug-sensitive and drug-resistant tuberculosis (TB).
- Trial name
- NCT01638520
- Testing
- Pascolizumab
- Where
- 7 sites in Malaysia, Philippines and 1 more
- Volunteers
- 32 people
- Sponsor
- National University Hospital, Singapore
Tuberculosis, Acute Coronary Syndrome
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD).
- Conditions
- Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis)
- Trial name
- Doxy-TB (NCT05473520)
- Testing
- Doxycycline
- Where
- 6 sites in Malaysia, Singapore
- Volunteers
- 150 people
- Sponsor
- National University Hospital, Singapore
Prevention of TB Recurrence
Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence
This is a Phase II/III trial with two groups of adults successfully cured of category 1 pulmonary TB receiving either VPM1002 or placebo.
- Trial name
- NCT03152903
- Testing
- VPM1002 (Recombinant BCG Vaccine)
- Where
- 10 sites in Bangladesh, India
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Tuberculosis, Pulmonary
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
This study is being done to test an experimental study vaccine compared to a placebo. The experimental study vaccine is called ID93 + GLA-SE.
- Trial name
- NCT06205589
- Testing
- ID93 + GLA-SE vaccine
- Volunteers
- 1,500 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Tuberculosis
Improving the Outcomes of Children With Tuberculosis Through Innovative Diagnostics and Treatment Monitoring
This study aims at identifying and evaluating novel diagnostic methods for children evaluated for respiratory tuberculosis. The investigators will use alternative samples like stool, urine, and masks to diagnose children with…
- Trial name
- RoGer Pedi (NCT06815588)
- Where
- Romania
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Research Center Borstel
Tuberculosis, Multidrug-Resistant
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial activity of bedaquiline (TMC207) in children and adolescents (0 months to less…
- Trial name
- NCT02354014
- Testing
- Bedaquiline (TMC207), Background Regimen (BR)
- Where
- 11 sites in Mozambique, Philippines and 4 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Tuberculosis
AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT
Tuberculosis (TB) kills 1.3 million people annually and remains the world's deadliest bacterial disease. The standard four-drug RIPE regimen achieves only 85% cure rates and causes drug-induced hepatotoxicity in 25-37% of…
- Trial name
- AIPH-TB-RCT-P2 (NCT07467252)
- Testing
- Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- Ministry of Health, Saudi Arabia
Tuberculosis, Post Tuberculosis
LIFE-TB ; Long-Term Impacts on Lung Health and Life After Tuberculosis in Korea
This is a prospective, multicenter observational cohort study aimed at establishing a nationwide post-TB lung disease registry in Korea.
- Trial name
- NCT06946784
- Where
- South Korea
- Volunteers
- 360 people
- Sponsor
- Yonsei University
Tuberculosis, Tuberculosis, Pulmonary
Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort
This study is a retrospective cohort study. The purpose of this study is to investigate clinical features of the patients with the cavitary pulmonary tuberculosis (TB) and endobronchial TB from the patients who have been…
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Cavity, Bronchoscopy
- Trial name
- NCT03822156
- Testing
- Observation of AFB smear/culture
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- University of Ulsan
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
Pulmonary Tuberculosis (TB)
Immune Reconstitution in Tuberculosis Disease
The aim with study is to provide adjunctive therapy with vitamin D and phenylbutyrate together with standard anti-tuberculosis treatment to significantly improve clinical recovery among patients with untreated, active pulmonary…
- Trial name
- IRETB (NCT01698476)
- Testing
- vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
- Where
- Ethiopia
- Volunteers
- 390 people
- Sponsor
- Karolinska Institutet